It began typically enough: the Supreme Court denied cert in Athena, Chargepoint and Trading Technologies; Brexit finally happened; the Federal Circuit refused to rehear Arthrex; and the IP community was waiting for important rulings in copyright cases like Google v. Oracle and trademark cases like Booking.com. But then came COVID. Courts and offices shut down, the USPTO went almost 100% remote, and all conferences and events were cancelled into 2021. At the same time, pharmaceuticals, vaccines – and the IP around them – became the only thing on anyone’s mind.
We Made it to November: The IP Community Gives Thanks in a Year Like No Other
No Comments
Patent
- Enablement
- Fee Shifting
- Litigation
- Justices Lean Toward Limiting, Not Eliminating, Assignor Estoppel Doctrine in Minerva v. Hologic
- Kappos at PTAB Masters Day 2: PTAB Problems Arose When It Failed to Evolve
- EPO Opposition Division Upholds NuCana Patent on Gilead’s Sovaldi, Highlighting Potential Flaws of CAFC Ruling in Gilead/Idenix
- Countries Like the Philippines are Unable to Utilize IP Flexibilities to Fight COVID-19
- Why the Patent Classification System Needs an Update
Recent Posts
- Justices Lean Toward Limiting, Not Eliminating, Assignor Estoppel Doctrine in Minerva v. Hologic
- Kappos at PTAB Masters Day 2: PTAB Problems Arose When It Failed to Evolve
- EPO Opposition Division Upholds NuCana Patent on Gilead’s Sovaldi, Highlighting Potential Flaws of CAFC Ruling in Gilead/Idenix
- Countries Like the Philippines are Unable to Utilize IP Flexibilities to Fight COVID-19
- Why the Patent Classification System Needs an Update